Summary
India Homeopathy Market report comprises market size, growth trends, key segments, competitive landscape, and future outlook. It highlights major players, demand drivers, consumer adoption trends, and the factors shaping homeopathy market growth in India.
Market Overview
India Homeopathy Market Overview
In 2023, the Indian Homeopathy Market was valued at INR 8.6 billion and is expected to reach INR 18.7 billion by 2029, growing at a CAGR of 13.8%. This growth is driven by the rising incidence of lifestyle diseases and health issues associated with smoking, alcohol, and drug abuse. The Indian subcontinent represents the largest market for homeopathy globally and has the highest number of homeopaths, despite homeopathy having originated in Germany. The market in India is expected to continue witnessing strong growth, supported by its position as the second-highest funded and used system within the AYUSH category, along with active support from both the government and the public.
Taxonomy
India Homeopathy Market Ecosystem
India Homeopathy Market Size (in INR Bn), 2018-2023
The Indian Homeopathy Market, valued at INR 5.2 billion in 2018, grew to INR 8.6 billion by 2023, registering a CAGR of 10.6%. This strong growth was supported by favorable policies and financial assistance from the Ministry of AYUSH, along with rising consumer awareness of natural and holistic healthcare approaches. Although the homeopathy market saw increased interest during the COVID-19 pandemic, supported by government measures such as the Ministry of AYUSH’s endorsement of homeopathic medicines for the prevention and management of COVID-19, the growth rate in 2020 and 2021 declined. This slowdown was mainly due to fewer visits to homeopathy clinics for minor and lifestyle-related issues, as people avoided in-person consultations to reduce the spread of the virus. Over the last two years, however, the market has shown a strong recovery with the easing of restrictions and the resumption of clinic visits.
India Homeopathy Industry Analysis
India Homeopathy Market Segmentation, 2023
India Homeopathy Market Segmentation by Region (in revenue %), 2023
The Australia Cold Chain market generated revenue of AUD 6,547.8 million in 2022, growing at a rate of 8.0%. The market is further expected to reach AUD 10,705.0 million by 2027, registering a CAGR of 10.03% during 2022–2027. Within the overall market, the Australia cold storage segment reached AUD 2,647.8 million in 2022, recording a CAGR of 9.7% during the historical period of 2017–2022. Meanwhile, the cold transport segment achieved a value of AUD 3,900.0 million in 2022, exhibiting a CAGR of 8.8% over the same historical period.
India Homeopathy Future Market Size
The India Homeopathy Market is expected to reach INR 18.7 Bn by 2029, expanding at a CAGR of 13.8%. This growth is likely to be driven by the rising prevalence of lifestyle-related conditions such as heart disease, stroke, obesity, and type 2 diabetes, along with illnesses linked to smoking, alcohol, and drug abuse. At the same time, increasing consumer preference for non-invasive treatment options is expected to strengthen market demand. The perception of homeopathic products as having no side effects is further contributing to their positive acceptance among consumers, supporting a broader rise in demand. In addition, growing awareness about the benefits of homeopathic medicine, along with strategic initiatives by key players and the government to promote its usage, is expected to further accelerate market growth.
India Homeopathy Market Company Profiles
| Company Name | Establishment year | Description |
|---|---|---|
Dr. Batra's | 1982 | Established in 1982 by Dr. Mukesh Batra, Dr Batra’s Healthcare is an Indian company specializing in homeopathy. While the organization was initially focused on homeopathy, it expanded its service portfolio in 2009 to include hair and skin-related treatments, followed by the addition of weight management and respiratory ailment segments. Today, Dr Batra’s Healthcare has a presence across five countries — India, the UK, the UAE, Bahrain, and Dhaka — with more than 200 clinics. The company operates through a mix of owned clinics, franchises, and a clinic-in-clinic model. Beyond its core healthcare offerings, the company has also diversified into pet care, media, and education. As part of its future strategy, Dr Batra’s aims to expand its FMCG portfolio across haircare, skincare, and personal care products. In addition, the company runs an in-house academy that offers a fellowship course in Homeopathic Dermatology for eligible doctors. |
Schwabe India | 1994 | Schwabe India is a subsidiary of Dr. Willmar Schwabe GmbH & Co. KG, a well-known German pharmaceutical company with a heritage dating back to 1866. Schwabe India offers a wide range of homeopathic medicines across various health conditions, supporting a holistic approach to wellness. International business accounts for roughly half of the group’s total turnover and forms an important part of its growth strategy, with the Schwabe Group currently expanding its marketing activities across five continents. In 1992, Schwabe Pharma AG was founded in Switzerland, and in the same year, Schwabe entered the US herbal medicine market through Nature’s Way, Inc. Dr. Willmar Schwabe India Pvt. Ltd. was established in 1994, when Schwabe also became a stakeholder in Austroplant Arzneimittel GmbH, Austria. |
SBL | 1983 | Established in 1983, the company was originally formed as Sharda Boiron Laboratories Ltd. through a collaboration with Laboratories Boiron of Lyon, France, a global leader in homeopathic medicines since 1932. The company later changed its name to SBL Pvt. Ltd., and today it is recognized as one of the leading homeopathic medicine manufacturing companies in India. Its advanced air-conditioned manufacturing facility in Sahibabad was built with support from Boiron and continues to maintain production and testing standards in line with international norms and global benchmarks. |
Lord’s | 1986 | Lord’s Homoeopathy was founded in 1986 with the vision of providing high-quality homeopathic remedies to the masses. In 1993, the company launched its first homoeopathic toothpaste, Lordent, which gained strong traction in the market, significantly enhanced the brand value of Lord’s, and added to its legacy. The company entered the international market in 2013, marking an important step in its expansion journey. In 2017, Lord’s further diversified its broad product portfolio by introducing a range of nutraceutical products aimed at meeting daily nutritional requirements through multivitamins and superfoods, while also addressing specific concerns related to skincare, weight loss, and bone and cartilage health. |
India Homeopathy Market Macro-Economic Factors
The central and state governments’ budgeted expenditure on healthcare touched 2.1 % of GDP in FY23, as per the Economic Survey 2022-23 tabled in Parliament by finance minister. This is forecasted to reach over 2.5 percent of the GDP by financial year 2025. This significant increase was predicted based on the likelihood of greater penetration of government health insurance in the country.
India currently has the largest population in the world and has overtaken top-ranking China in 2023. Its residents comprise more than one-seventh of the entire world’s population, and despite a slowly decreasing fertility rate (which still exceeds the replacement rate and keeps the median age of the population relatively low), an increasing life expectancy adds to an expanding population.
The overall investment climate in the country, including foreign direct investment (FDI) in healthcare, influences the development and expansion of the homeopathy market. The MedTech FDI inflow in India for the first quarter of 2023 was around $39 million, which rose to $301 million in the second quarter. For the third quarter, the figures were $124 million, with a cumulative total inflow of $464 million for January-September 2023.
Frequently Asked Questions
Find quick answers to common questions about the India Homeopathy Market